文献速递神经儿科影像MR

钆对比剂在急诊儿童癫痫初始评估中的效用

Utility of Gadolinium-Based Contrast in Initial Evaluation of Seizures in Children Presenting Emergently.
PubMed 文献 · AJNR Am J Neuroradiol · 2023-08-31

回顾性纳入2016年10月1日至2021年9月30日因新发癫痫至急诊或住院并接受脑MR检查的儿童患者共1884例,524例(28%)有潜在致痫性发现,874例(46%)使用了静脉钆对比剂,其中仅48例(5%)回顾性认为有必要使用;1010例初次平扫患者中15例(1.5%)需再次增强MR进一步评估。作者结论认为钆对比剂在多数急性儿童癫痫影像评估中附加获益有限。

要点

  • 儿童急性癫痫MR中仅5%(48/874)增强病例回顾性认为钆对比剂有必要。
  • 致痫性病变以神经发育性病变142例(27%)最常见,其次为颅内出血89例(17%)。
  • 1010例初次平扫者中仅1.5%(15例)需再次增强MR进一步评估。

核心结论

  • 作者结论认为,在多数急性儿童癫痫患者的影像评估中,钆对比剂的附加获益有限。

研究设计与样本

  • 回顾性研究,连续纳入2016年10月1日至2021年9月30日因新发癫痫至急诊和/或住院并接受脑MR检查的儿童患者,共1884例,记录年龄、性别、静脉钆使用及癫痫病因。

关键影像表现/征象

  • 524例(28%)有潜在致痫性发现,1153例(61%)正常,207例(11%)为非特异性信号改变。
  • 致痫性发现分类:神经发育性病变142例(27%)、颅内出血(外伤性或生发基质)89例(17%)、缺血/缺氧性62例(12%)、海马硬化44例(8%)、肿瘤性38例(7%)、免疫/感染性20例(4%)、斑痣性错构瘤病19例(4%)、血管畸形17例(3%)、代谢性3例(<1%)、其他90例(17%)。

诊断标准与关键数值

  • 874例(46%)接受静脉钆对比剂,其中仅48例(5%)回顾性认为有必要使用;48例中免疫/感染性15例(31%)、肿瘤性33例(69%)。
  • 1010例初次平扫患者中,15例(1.5%)需再次增强MR以进一步评估所见。

临床应用与阅片要点

  • 作者结论提示,在多数急性儿童癫痫的影像评估中,钆对比剂的附加获益有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: The frequency and utility of gadolinium in evaluation of acute pediatric seizure presentation is not well known. The purpose of this study was to assess the utility of gadolinium-based contrast agents in MR imaging performed for the evaluation of acute pediatric seizure presentation.

MATERIALS AND METHODS: We identified consecutive pediatric patients with new-onset seizures from October 1, 2016, to September 30, 2021, who presented to the emergency department and/or were admitted to the inpatient unit and had an MR imaging of the brain for the evaluation of seizures. The clinical and imaging data were recorded, including the patient's age and sex, the use of IV gadolinium, and the underlying cause of epilepsy when available.

RESULTS: A total of 1884 patients were identified for inclusion. Five hundred twenty-four (28%) patients had potential epileptogenic findings on brain MR imaging, while 1153 (61%) patients had studies with normal findings and 207 (11%) patients had nonspecific signal changes. Epileptogenic findings were subclassified as the following: neurodevelopmental lesions, 142 (27%); intracranial hemorrhage (traumatic or germinal matrix), 89 (17%); ischemic/hypoxic, 62 (12%); hippocampal sclerosis, 44 (8%); neoplastic, 38 (7%); immune/infectious, 20 (4%); phakomatoses, 19 (4%); vascular anomalies, 17 (3%); metabolic, 3 (<1%); and other, 90 (17%). Eight hundred seventy-four (46%) patients received IV gadolinium. Of those, only 48 (5%) cases were retrospectively deemed to have necessitated the use of IV gadolinium: Fifteen of 48 (31%) cases were subclassified as immune/infectious, while 33 (69%) were neoplastic. Of the 1010 patients with an initial noncontrast study, 15 (1.5%) required repeat MR imaging with IV contrast to further evaluate the findings.

CONCLUSIONS: Gadolinium contrast is of limited additive benefit in the imaging of patients with an acute onset of pediatric seizures in most instances.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Andrijauskis D, Woolf G, Kuehne A, et al. Utility of Gadolinium-Based Contrast in Initial Evaluation of Seizures in Children Presenting Emergently. AJNR Am J Neuroradiol. 2023. PMID: 37652579. doi:10.3174/ajnr.A7976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。